The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA Vaccine

Mol Cells. 2022 Oct 31;45(10):738-748. doi: 10.14348/molcells.2022.0031. Epub 2022 Jul 28.


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has posed a serious threat to global public health. A novel vaccine made from messenger RNA (mRNA) has been developed and approved for use at an unprecedented pace. However, an increased risk of myocarditis has been reported after BNT162b2 mRNA vaccination due to unknown causes. In this study, we used single-cell RNA sequencing and single-cell T cell receptor sequencing analyses of peripheral blood mononuclear cells (PBMCs) to describe, for the first time, changes in the peripheral immune landscape of a patient who underwent myocarditis after BNT162b2 vaccination. The greatest changes were observed in the transcriptomic profile of monocytes in terms of the number of differentially expressed genes. When compared to the transcriptome of PBMCs from vaccinated individuals without complications, increased expression levels of IL7R were detected in multiple cell clusters. Overall, results from this study can help advance research into the pathogenesis of BNT162b2-induced myocarditis.

Keywords: BNT162b2; myocarditis; peripheral blood mononucleear cells; severe acute respiratory syndrome coronavirus 2; single-cell RNA sequencing.

MeSH terms

  • BNT162 Vaccine
  • COVID-19*
  • Humans
  • Leukocytes, Mononuclear
  • Myocarditis* / etiology
  • RNA, Messenger / genetics
  • SARS-CoV-2 / genetics
  • Vaccines, Synthetic
  • Viral Vaccines*
  • mRNA Vaccines


  • RNA, Messenger
  • Vaccines, Synthetic
  • Viral Vaccines
  • mRNA Vaccine
  • mRNA Vaccines
  • BNT162 Vaccine